A Phase 2 interventional study of EDP-305 Dose 1 and EDP-305 Dose 2 in Non-Alcoholic Steatohepatitis, sponsored by Enanta Pharmaceuticals, Inc. Completed at 82 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-09-16.
Sponsored by Enanta Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 118th largest by enrollment of the 460 interventional ones that give a count, is one of 36 that started in 2018, is one of 192 in phase 2, and was the 227th registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 36 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 134 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
Enanta Pharmaceuticals, Inc is the lead sponsor of 46 studies on the registry; 3 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
Enanta Pharmaceuticals, Inc has 7 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with Non-Alcoholic Steatohepatitis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female with presence of NASH by:
Exclusion Criteria:
Laboratory Screening Results:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will take 2 tablets once a day orally for 12 weeks
Drug: EDP-305 Dose 1
Subjects will take 2 tablets once a day orally for 12 weeks
Drug: EDP-305 Dose 2
Subjects will take 2 tablets once a day orally for 12 weeks
Drug: Placebo
Two tablets daily for 12 weeks
Two tablets daily for 12 weeks
Two tablets daily for 12 weeks
Mean Change From Baseline (Average) in Alanine Aminotransferase (ALT) at Week 12
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ALT level. Baseline refers to the average of the screening and the Day 1 values; if either the screening or Day 1 values were missing, the non-missing value was used. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Baseline and Week 12
Mean Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) at Week 12
The liver fat percentage was assessed by MRI-PDFF, which is an established method that enables the quantification of fat content in the liver; the value of liver fat is expressed in percentage and ranges from 0 to 100% with higher values representing higher liver fat level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Baseline and Week 12
Mean Change From Baseline in Aspartate Aminotransferase to Platelet Ratio Index (APRI) at Week 12
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the aspartate aminotransferase (AST) level and platelet count. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. The APRI score (AST to platelet ratio index) is an index comprised of biochemical values and is used to determine the degree of hepatic fibrosis. APRI is calculated from the level of AST measured in a blood test (international units per liter \[IU/L\]) and platelet count (10\^9/L) according to the following formula: APRI = (\[AST value in IU/L / upper limit of the normal range of AST\] / \[platelet count in 10\^9/L\]) × 100. In general, APRI scores range from 0 to \>2.0, where scores \<0.5 indicate no significant fibrosis, scores \>1.5 indicate significant fibrosis, and scores \>2.0 have been shown to be best correlated with the presence of cirrhosis. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Baseline and Week 12
Mean Change From Baseline in Triglycerides (TG) at Week 12
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the TG level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Baseline and Week 12
Mean Change From Baseline in Total Cholesterol at Week 12
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the total cholesterol level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Baseline and Week 12
Mean Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the HDL-C level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Baseline and Week 12
Mean Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the LDL-C level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Baseline and Week 12
Mean Change From Baseline in Adiponectin at Week 12
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the adiponectin level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Baseline and Week 12
Mean Change From Baseline in Apolipoproteins A1 (ApoA-1) at Week 12
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ApoA-1 level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Baseline and Week 12
Mean Change From Baseline in Apolipoproteins B (ApoB) at Week 12
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ApoB level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Baseline and Week 12
Mean Change From Baseline in Apolipoproteins C3 (ApoC3) at Week 12
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ApoC3 level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Baseline and Week 12
Mean Change From Baseline in Fasting Blood Glucose at Week 12
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the fasting glucose level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Baseline and Week 12
Mean Change From Baseline in Fasting Insulin at Week 12
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the fasting insulin (in micro International units per milliliter \[μIU/mL\]). Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Baseline and Week 12
Mean Change From Baseline in Homeostasis Model Assessment (HOMA) Index for Nondiabetic Participants at Week 12
Blood samples were collected at specific timepoints for the laboratory evaluation; from the results of fasting glucose and insulin, an insulin resistance (IR) was estimated for the nondiabetic participants using the HOMA-IR computer algorithm. A higher HOMA-IR indicates a higher degree of insulin resistance. Participants who were not considered as having type 2 diabetes mellitus (T2DM) were identified as nondiabetic. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Baseline and Week 12
Mean Change From Baseline in HOMA Index for Diabetic Participants at Week 12
Blood samples were collected at specific timepoints for the laboratory evaluation; from the results of fasting glucose and insulin, an insulin resistance (IR) was estimated for the nondiabetic participants using the HOMA-IR computer algorithm. A higher HOMA-IR indicates a higher degree of insulin resistance. Participants who were considered as having T2DM were identified as diabetic. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Baseline and Week 12
Mean Change From Baseline in Glycated Hemoglobin (HbA1c) in Participants With T2DM at Week 12
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the HbA1c. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Baseline and Week 12
Maximum Plasma Concentration (Cmax) of EDP-305 on Day 1 and Week 12
The Cmax is the maximum observed plasma concentration, which was measured for EDP-305 on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the Pharmacokinetic (PK) Population.
Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Time to Reach Maximum Plasma Concentration (Tmax) of EDP-305 on Day 1 and at Week 12
The Tmax was measured for EDP-305 on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC[Last]) of EDP-305 on Day 1 and at Week 12
AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EDP-305 on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Cmax of EP-022571 on Day 1 and at Week 12
The Cmax is the maximum observed plasma concentration, which was measured for EP-022571 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Tmax of EP-022571 on Day 1 and at Week 12
The Tmax was measured for EP-022571 (a metabolite of EDP-305) on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
AUC(Last) of EP-022571 on Day 1 and at Week 12
AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EP-022571 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Cmax of EP-022572 on Day 1 and at Week 12
The Cmax is the maximum observed plasma concentration, which was measured for EP-022572 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Tmax of EP-022572 on Day 1 and at Week 12
The Tmax was measured for EP-022572 (a metabolite of EDP-305) on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
AUC(Last) of EP-022572 on Day 1 and at Week 12
AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EP-022572 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Cmax of EP-022679 on Day 1 and at Week 12
The Cmax is the maximum observed plasma concentration, which was measured for EP-022679 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Tmax of EP-022679 on Day 1 and at Week 12
The Tmax was measured for EP-022679 (a metabolite of EDP-305) on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
AUC(Last) of EP-022679 on Day 1 and at Week 12
AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EP-022679 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Mean Change From Baseline in Body Weight at Week 12
Body weight was measured at specific timepoints for the participants. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Baseline and Week 12
Mean Change From Baseline in Waist to Hip (WTH) Ratio at Week 12
The WTH ratio is calculated as the ratio of waist to hip circumference, which was measured at specific timepoints. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Baseline and Week 12
Mean Change From Baseline in Fibroblast Growth Factor 19 (FGF19) by Nominal Timepoint (Intensive Pharmacodynamic [PD] Samples) at Week 12
Blood samples were collected according to the intensive sampling scheme at specific timepoints to assess the PD marker: FGF19. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and Day 84 (Week 12)
Mean Change From Baseline in FGF19 by Bin Timepoint (Sparse PD Samples) at Week 12
Blood samples were collected according to the sparse sampling scheme at specific timepoints to assess the PD marker: FGF19. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Predose and two samples postdose (first sample between 1 to 3 hours postdose and second sample 1 hour later than fist sample) on Day 1 and Day 84 (Week 12)
Mean Change From Baseline in 7a-Hydroxy-4-Cholestene-3-One (C4) by Nominal Timepoint (Intensive PD Samples) at Week 12
Blood samples were collected according to the intensive sampling scheme at specific timepoints to assess the PD marker: C4. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and Day 84 (Week 12)
Mean Change From Baseline in C4 by Bin Timepoint (Sparse PD Samples) at Week 12
Blood samples were collected according to the sparse sampling scheme at specific timepoints to assess the PD marker: C4. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Predose and two samples postdose (first sample between 1 to 3 hours postdose and second sample 1 hour later than fist sample) on Day 1 and Day 84 (Week 12)
Mean Change From Baseline in Bile Acid (BA) by Nominal Timepoint (Intensive PD Samples) at Week 12
Blood samples were collected according to the intensive sampling scheme at specific timepoints to assess the PD marker: BA. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and Day 84 (Week 12)
Mean Change From Baseline in BA by Bin Timepoint (Sparse PD Samples) at Week 12
Blood samples were collected according to the sparse sampling scheme at specific timepoints to assess the PD marker: BA. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Time frame: Predose and two samples postdose (first sample between 1 to 3 hours postdose and second sample 1 hour later than fist sample) on Day 1 and Day 84 (Week 12)
| Milestone | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Started | 24 | 55 | 53 |
| Completed | 18 | 49 | 39 |
| Not completed | 6 | 6 | 14 |
| Withdrew: Adverse event | 2 | 1 | 12 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 |
| Withdrew: Withdrawal by subject | 3 | 2 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Participant met stopping rules | 0 | 1 | 0 |
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ALT level. Baseline refers to the average of the screening and the Day 1 values; if either the screening or Day 1 values were missing, the non-missing value was used. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| units per liter (U/L) | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline (Average) in Alanine Aminotransferase (ALT) at Week 12 | -13.85 ± 18.151 | -23.76 ± 28.135 | -26.14 ± 33.328 |
The liver fat percentage was assessed by MRI-PDFF, which is an established method that enables the quantification of fat content in the liver; the value of liver fat is expressed in percentage and ranges from 0 to 100% with higher values representing higher liver fat level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| percentage of fat | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) at Week 12 | -2.842 ± 4.4687 | -3.759 ± 5.1600 | -6.428 ± 7.2586 |
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the aspartate aminotransferase (AST) level and platelet count. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. The APRI score (AST to platelet ratio index) is an index comprised of biochemical values and is used to determine the degree of hepatic fibrosis. APRI is calculated from the level of AST measured in a blood test (international units per liter \[IU/L\]) and platelet count (10\^9/L) according to the following formula: APRI = (\[AST value in IU/L / upper limit of the normal range of AST\] / \[platelet count in 10\^9/L\]) × 100. In general, APRI scores range from 0 to \>2.0, where scores \<0.5 indicate no significant fibrosis, scores \>1.5 indicate significant fibrosis, and scores \>2.0 have been shown to be best correlated with the presence of cirrhosis. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| ratio | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in Aspartate Aminotransferase to Platelet Ratio Index (APRI) at Week 12 | -0.180 ± 0.3462 | -0.107 ± 0.3396 | -0.194 ± 0.3533 |
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the TG level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| millimoles per liter (mmol/L) | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in Triglycerides (TG) at Week 12 | -0.151 ± 0.8529 | -0.366 ± 1.5858 | 0.129 ± 1.1088 |
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the total cholesterol level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| mmol/L | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in Total Cholesterol at Week 12 | -0.175 ± 0.6879 | 0.046 ± 0.6697 | -0.003 ± 1.0046 |
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the HDL-C level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| mmol/L | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12 | 0.008 ± 0.1279 | -0.058 ± 0.1670 | -0.210 ± 0.2708 |
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the LDL-C level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| mmol/L | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 | -0.112 ± 0.6431 | 0.129 ± 0.5099 | 0.151 ± 0.8157 |
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the adiponectin level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| nanogram per milliliter (ng/mL) | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in Adiponectin at Week 12 | 319.16 ± 689.387 | 17.94 ± 828.494 | 522.00 ± 2649.701 |
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ApoA-1 level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| proteins*10^9/L | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in Apolipoproteins A1 (ApoA-1) at Week 12 | -0.074 ± 0.1514 | -0.107 ± 0.1671 | -0.226 ± 0.2197 |
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ApoB level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| proteins*10^9/L | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in Apolipoproteins B (ApoB) at Week 12 | -0.028 ± 0.1687 | 0.040 ± 0.1781 | 0.099 ± 0.2898 |
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ApoC3 level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| proteins*10^9/L | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in Apolipoproteins C3 (ApoC3) at Week 12 | -0.0094 ± 0.04388 | -0.0167 ± 0.03918 | -0.0122 ± 0.05721 |
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the fasting glucose level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| mmol/L | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in Fasting Blood Glucose at Week 12 | -0.11 ± 2.130 | 0.48 ± 1.847 | 1.68 ± 3.396 |
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the fasting insulin (in micro International units per milliliter \[μIU/mL\]). Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| μIU/mL | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in Fasting Insulin at Week 12 | -0.688 ± 9.2808 | 2.528 ± 14.6947 | -5.635 ± 52.7637 |
Blood samples were collected at specific timepoints for the laboratory evaluation; from the results of fasting glucose and insulin, an insulin resistance (IR) was estimated for the nondiabetic participants using the HOMA-IR computer algorithm. A higher HOMA-IR indicates a higher degree of insulin resistance. Participants who were not considered as having type 2 diabetes mellitus (T2DM) were identified as nondiabetic. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| units on a scale | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in Homeostasis Model Assessment (HOMA) Index for Nondiabetic Participants at Week 12 | 0.587 ± 2.0088 | 0.192 ± 2.7180 | -6.474 ± 24.9369 |
Blood samples were collected at specific timepoints for the laboratory evaluation; from the results of fasting glucose and insulin, an insulin resistance (IR) was estimated for the nondiabetic participants using the HOMA-IR computer algorithm. A higher HOMA-IR indicates a higher degree of insulin resistance. Participants who were considered as having T2DM were identified as diabetic. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| units on a scale | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in HOMA Index for Diabetic Participants at Week 12 | -0.493 ± 6.2624 | 2.088 ± 6.6114 | 5.059 ± 15.0113 |
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the HbA1c. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| percentage of glycated hemoglobin | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in Glycated Hemoglobin (HbA1c) in Participants With T2DM at Week 12 | 0.31 ± 0.685 | 0.21 ± 0.776 | 0.76 ± 0.963 |
The Cmax is the maximum observed plasma concentration, which was measured for EDP-305 on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the Pharmacokinetic (PK) Population.
| ng/mL | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|
| Day 1 | 11.1 ± 105 | 25.1 ± 101 |
| Week 12 | 15.9 ± 105 | 41.1 ± 101 |
The Tmax was measured for EDP-305 on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
| hours (h) | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|
| Day 1 | 6.00 (2.00 to 8.07) | 6.00 (2.00 to 8.25) |
| Week 12 | 6.00 (0.00 to 8.02) | 6.00 (0.00 to 8.18) |
AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EDP-305 on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
| hour*nanogram per milliliter (h*ng/mL) | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|
| Day 1 | 53.6 ± 101 | 129 ± 100 |
| Week 12 | 87.2 ± 101 | 264 ± 100 |
The Cmax is the maximum observed plasma concentration, which was measured for EP-022571 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
| ng/mL | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|
| Day 1 | 0.324 ± 983 | 0.833 ± 177 |
| Week 12 | 0.296 ± 1549 | 0.787 ± 233 |
The Tmax was measured for EP-022571 (a metabolite of EDP-305) on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
| h | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|
| Day 1 | 6.00 (2.00 to 8.00) | 6.00 (1.93 to 8.25) |
| Week 12 | 6.00 (0.00 to 8.00) | 6.00 (0.00 to 6.15) |
AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EP-022571 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
| h*ng/mL | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|
| Day 1 | 1.48 ± 174 | 3.77 ± 112 |
| Week 12 | 1.41 ± 187.01 | 3.81 ± 121.18 |
The Cmax is the maximum observed plasma concentration, which was measured for EP-022572 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
| ng/mL | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|
| Day 1 | 0.234 ± 1942 | 0.571 ± 212 |
| Week 12 | 0.214 ± 2863 | 0.556 ± 212 |
The Tmax was measured for EP-022572 (a metabolite of EDP-305) on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
| h | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|
| Day 1 | 6.00 (2.00 to 8.07) | 6.00 (2.00 to 8.00) |
| Week 12 | 6.00 (0.00 to 8.00) | 2.05 (0.00 to 8.18) |
AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EP-022572 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
| h*ng/mL | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|
| Day 1 | 1.06 ± 220 | 2.92 ± 114 |
| Week 12 | 1.13 ± 212 | 3.19 ± 116 |
The Cmax is the maximum observed plasma concentration, which was measured for EP-022679 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
| ng/mL | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|
| Day 1 | 0.574 ± 321 | 1.28 ± 167 |
| Week 12 | 1.41 ± 117 | 3.85 ± 122 |
The Tmax was measured for EP-022679 (a metabolite of EDP-305) on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
| h | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|
| Day 1 | 8.00 (5.88 to 8.00) | 8.00 (6.00 to 8.25) |
| Week 12 | 6.03 (0.00 to 8.00) | 6.00 (0.00 to 8.18) |
AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EP-022679 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
| h*ng/mL | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|
| Day 1 | 2.32 ± 137.54 | 5.09 ± 117 |
| Week 12 | 7.14 ± 113 | 22.5 ± 104 |
Body weight was measured at specific timepoints for the participants. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| kilograms (kg) | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in Body Weight at Week 12 | -0.877 ± 2.8100 | -1.440 ± 2.7984 | -2.114 ± 3.2829 |
The WTH ratio is calculated as the ratio of waist to hip circumference, which was measured at specific timepoints. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| ratio | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in Waist to Hip (WTH) Ratio at Week 12 | 0.013 ± 0.0729 | -0.007 ± 0.0477 | 0.014 ± 0.0509 |
Blood samples were collected according to the intensive sampling scheme at specific timepoints to assess the PD marker: FGF19. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| nanogram per liter (ng/L) | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in Fibroblast Growth Factor 19 (FGF19) by Nominal Timepoint (Intensive Pharmacodynamic [PD] Samples) at Week 12 | 159.98 ± 165.245 | 410.00 ± 260.223 | 607.12 ± 891.553 |
Blood samples were collected according to the sparse sampling scheme at specific timepoints to assess the PD marker: FGF19. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| ng/L | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in FGF19 by Bin Timepoint (Sparse PD Samples) at Week 12 | 33.51 ± 155.744 | 46.04 ± 88.662 | 813.29 ± 3200.567 |
Blood samples were collected according to the intensive sampling scheme at specific timepoints to assess the PD marker: C4. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| ng/mL | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in 7a-Hydroxy-4-Cholestene-3-One (C4) by Nominal Timepoint (Intensive PD Samples) at Week 12 | -9.484 ± 20.6295 | -36.783 ± 24.6560 | -40.567 ± 20.9260 |
Blood samples were collected according to the sparse sampling scheme at specific timepoints to assess the PD marker: C4. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| ng/mL | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in C4 by Bin Timepoint (Sparse PD Samples) at Week 12 | -5.242 ± 30.5321 | -13.500 ± 26.2458 | -23.773 ± 20.7045 |
Blood samples were collected according to the intensive sampling scheme at specific timepoints to assess the PD marker: BA. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| micromoles per liter (μmol/L) | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in Bile Acid (BA) by Nominal Timepoint (Intensive PD Samples) at Week 12 | 4.47 ± 3.668 | 2.16 ± 5.507 | 0.14 ± 3.125 |
Blood samples were collected according to the sparse sampling scheme at specific timepoints to assess the PD marker: BA. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
| μmol/L | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Mean Change From Baseline in BA by Bin Timepoint (Sparse PD Samples) at Week 12 | 0.77 ± 5.789 | -0.11 ± 2.783 | 0.74 ± 4.091 |
Collected over Adverse events (AEs) were reported from the date of signing the consent form to the date of completion of the participant's end of the study visit (Week 16). Ongoing AEs were followed beyond the end of the study visit at the discretion of the investigator.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/24 (0%) | 1/24 (4.2%) | 8/24 (33.3%) |
| EDP-305 1 mg | 0/55 (0%) | 1/55 (1.8%) | 17/55 (30.9%) |
| EDP-305 2.5 mg | 0/53 (0%) | 0/53 (0%) | 32/53 (60.4%) |
| Event | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Cerebrovascular accidentNervous system disorders | 1/24 | 0/55 | 0/53 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/24 | 1/55 | 0/53 |
| Event | Placebo | EDP-305 1 mg | EDP-305 2.5 mg |
|---|---|---|---|
| Pruritus generalisedSkin and subcutaneous tissue disorders | 1/24 | 5/55 | 25/53 |
| VomitingGastrointestinal disorders | 2/24 | 1/55 | 1/53 |
| HeadacheNervous system disorders | 2/24 | 2/55 | 2/53 |
| FatigueGeneral disorders | 2/24 | 2/55 | 2/53 |
| RashSkin and subcutaneous tissue disorders | 0/24 | 1/55 | 4/53 |
| PruritusSkin and subcutaneous tissue disorders | 1/24 | 0/55 | 3/53 |
| DiarrhoeaGastrointestinal disorders | 0/24 | 2/55 | 3/53 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/24 | 1/55 | 3/53 |
| NauseaGastrointestinal disorders | 1/24 | 3/55 | 2/53 |
| Urinary tract infectionInfections and infestations | 0/24 | 3/55 | 1/53 |
Demographics were summarized for the Safety Population, which included all the randomized participants who received at least one dose of the study treatment. The numbers of participants included in the Efficacy Population were same as the Safety Population.
| Age, Customized(Participants) | Placebo | EDP-305 1 mg | EDP-305 2.5 mg | Total |
|---|---|---|---|---|
| <65 years | 22 | 52 | 46 | 120 |
| ≥65 years | 2 | 3 | 7 | 12 |
| Sex: Female, Male(Participants) | Placebo | EDP-305 1 mg | EDP-305 2.5 mg | Total |
|---|---|---|---|---|
| Female | 11 | 29 | 29 | 69 |
| Male | 13 | 26 | 24 | 63 |
| Race/Ethnicity, Customized(Participants) | Placebo | EDP-305 1 mg | EDP-305 2.5 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 1 | 7 | 3 | 11 |
| Black or African American | 2 | 1 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| White | 17 | 42 | 47 | 106 |
| Not reported | 2 | 2 | 1 | 5 |
| Other | 0 | 0 | 1 | 1 |
| Mexican | 1 | 1 | 1 | 3 |
| Not specified | 0 | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2018 to primary completion in Jun 2019, 13 months.
Results were first posted in Sep 2021, 2 years 3 months after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 13 months is below that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: EDP-305
Non-alcoholic Fatty Liver Disease →